$QBIO The Company is focused on our current approv
Post# of 36977
(Total Views: 114)
Posted On: 10/27/2021 9:56:30 AM
$QBIO The Company is focused on our current approved radiopharmaceutical product and is assessing additional assets within the same vertical to grow the future revenue opportunities. We have also learned that as of Oct 19th with immediate effect, our direct competitor in the cancer pain palliation space is no longer producing QUADRAMET® (Samarium Sm 153 Lexidronam Injection).We have already seen an uptick in product enquiry as result. In addition, together with Mannin Research we have de-risked the Mannin platform with successful proof of concept data and fully funded clinical trials expected to start in early 2022. Continued success in this platform opens the opportunity for over $200 million in potential license revenues in several indications including infectious diseases (COVID19), kidney disease, cardiovascular disease, and glaucoma.
QBIO
QBIO
(0)
(0)Scroll down for more posts ▼